Clínic Hospital

Single and repeated intravenous ketamine infusions are effective in reducing suicidal and depressive symptoms in patients with an acute episode of major depression. These are the main conclusions of a systematic review and meta-analysis published today in the journal JAMA Psychiatry, which also notes that long-term outcomes are not well established.

The Ministry of Health has announced that Spain will receive the MV Hondius in the Canary Islands “in accordance with international law and the spirit of humanitarianism”. The government is thus responding to a request from the World Health Organisation (WHO) and the European Union for the cruise ship, which is travelling from Argentina and has an outbreak of hantavirus on board, to dock in the Canary Islands, in the port of Granadilla, Tenerife. The European Centre for Disease Prevention and Control has assessed which passengers should be evacuated from the ship to Cape Verde, where it is currently located, and which will continue on to the Canary Islands. Once there, they will be examined and transferred to their home countries in accordance with safety protocols. The cruise ship is expected to arrive in the archipelago in three or four days.

The hallucinogen psilocybin, found in certain mushrooms, is being investigated as a treatment for conditions such as depression. A study published in Nature Communications shows that a single 25 mg dose of the compound can produce brain changes lasting up to a month after administration. These were measured using neuroimaging techniques in 28 healthy adults who had never taken psychedelics. In terms of psychological effects, participants showed increased cognitive flexibility, psychological insight, and well-being after one month.

A review published in The Lancet Psychiatry has examined the prevalence of major depressive disorder during pregnancy, the peripartum period—immediately before and after childbirth—and the postpartum period—up to twelve months after childbirth. The study, which used data from more than two million women and girls aged 10 to 59 from all regions of the world, showed that approximately one in 15 (6.8%) is affected by major depression during the year following childbirth and that the prevalence was highest during the first two weeks after childbirth (8.3%). The authors call for greater integration of screening, prevention, and treatment of this disorder during the peripartum period into current care models.

One of the best-known genetic risk factors for developing Parkinson’s disease is carrying variants of the GBA1 gene. A new study published in the journal Nature Medicine compared the microbiomes of 43 carriers of this gene who had not developed the disease with those of 271 Parkinson’s patients and 150 healthy individuals. The results showed, in addition to alterations in the microbiome in the patient group, that 25% of the microbiome of carriers of this gene exhibited alterations, representing an intermediate profile between the other two groups. The results were validated using independent cohorts from the United Kingdom, South Korea, and Turkey. According to the authors, “alterations in the gut microbiome can identify individuals with both genetic and non-genetic risk in the general population who may be progressing toward Parkinson’s disease.”
 

For the first time, CAR-T cell therapy has been used to treat a patient with three different autoimmune diseases – autoimmune haemolytic anaemia, immune thrombocytopenia and antiphospholipid syndrome – which were life-threatening and had resisted years of treatment. The patient, who previously required daily blood transfusions, has been in remission for a year without the need for further treatment since then. The case report, published in the journal Med, suggests that these therapies may help treat complex and severe autoimmune diseases. 

Individualised dosing of a synthetic inhalable formulation of mebufotenine, a psychedelic substance, led to improvements in depressive symptoms compared with placebo and was well tolerated. These are the results of a phase 2 clinical trial published in the journal JAMA Psychiatry, which includes Spanish participation. According to the authors, this supports its potential as a novel, fast-acting treatment for treatment-resistant depression.

Cancer patients receiving a type of immunotherapy known as Immune Checkpoint Inhibitor (ICI) have a higher risk of serious adverse events, such as aortic aneurysm rupture, interstitial lung disease, myositis and liver failure, according to a study published in PNAS. "Establishing formal contraindications for ICI users seems warranted," concludes the analysis, based on more than 290,000 cases from pharmacovigilance databases of the US Food and Drug Administration and the World Health Organisation.

The combination of the antiretrovirals bictegravir and lenacapavir in a single tablet allows HIV treatment —previously based on multiple daily medications— to be simplified, according to the results of a new phase 3 clinical trial published in The Lancet. The trial, which included over 550 people living with HIV from 15 countries with a median age of 60, showed that the new treatment was just as effective at maintaining viral suppression as multi-drug regimens. Most participants were taking between two and eleven tablets daily, and around 40 % were on antiretrovirals more than once a day. The results were presented at the 2026 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, USA.

The study of psychedelic drugs in pharmacological treatments had its eureka moment with chemist Albert Hofmann's famous bike ride under the influence of LSD in 1938 and then developed over decades, but with Richard Nixon it was shelved. In recent years, it has resurfaced in hospitals and laboratories around the world. Last week, the Congress of Deputies hosted a conference on these substances. We explain what they are, what they are used for, the current state of research, and their risks, with the help of expert sources.